REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
23 May 2023
REPROCELL will now offer CDMO services to manufacture ATMPs generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
End of Q4 update from REPROCELL (2022-23)
04 May 2023
Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO you can find out more here.
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
03 May 2023
REPROCELL USA has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “HARMONIC”.
Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chikafumi Yokoyama
28 February 2023
On February 26 2023 REPROCELL celebrated its 20th anniversary. In this letter, the company CEO reflects on the history of REPROCELL to the present day.
End of Q3 update from REPROCELL (2022-23)
12 December 2022
The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug discovery research.
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
09 December 2022
The three-month study, conducted at REPROCELL, will assess the binding affinity of the peptide in healthy human and RA synovial tissue.
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
23 November 2022
REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.
Building economic resilience and unleashing productivity through digital innovation
09 November 2022
CEO of REPROCELL said his company was among those that had received support from HNCDI to help it develop new approaches to drug development.
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
13 October 2022
REPROCELL Inc. and JTB Corp. will begin marketing Personal iPS (REPROCELL's iPSC storage and production service) overseas through the JMHC.
REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
05 October 2022
Learn why REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program.